European Union has decided to request the US to give the authorization for the export of millions of doses of AstraZeneca’s (NASDAQ: AZN) coronavirus vaccine to Europe. The EU also disclosed that Washington must guarantee the free flow of deliveries of vital vaccine components required in European manufacturing.

Furthermore, EC stated: “We are confident that we can collaborate with the U.S. to guarantee that the vaccines manufactured or preserved in the U.S. for the completion of vaccine manufacturers' obligations under the contract with the EU will be fully revered.”

AstraZeneca Plc (NASDAQ: AZN) shares were soared 1.76% at $48.06 during the trading session of Friday. AstraZeneca's share price went from a low point around $36.15 to briefly over $64.94 in the past 52 weeks, though shares have since pulled back to $48.06. AZN's market cap has remained high, hitting $129.25 billion at the time of writing.

Looking at its liquidity, it has a current ratio of 1.00 and a quick ratio of 0.80. The firm has total debt to equity ratio of 1.30. If we look at the recent analyst rating of AZN, UBS has upgraded the rating of AZN shares and increased the rating from Neutral to Buy.